Sign in

CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company

Cullinan Therapeutics, Inc.

Sign in to watch
Ticker
CGEM
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
813879991
Phone
617-410-4650
Business address
ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
Former names
Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
  1. 4 Open-market sale Chief Scientific Officer sold 2,898 shares at $9.67 ($28,024)
  2. 144 Insider Sale of Securities
  3. 4 Planned sale Chief Scientific Officer sold 3,143 shares at an average $12.23 ($38,433)
  4. 144 Insider Sale of Securities
  5. 8-K Event Regulation FD disclosure · Other events
  6. 4 Planned sale Chief Scientific Officer sold 4,000 shares at $12.30 ($49,200)
  7. 144 Insider Sale of Securities
  8. 8-K Event Agreement ended
  9. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  10. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  11. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  12. 10-Q Report Quarterly Report
  13. 8-K Event Results of operations · Other events
  14. 8-K Event Regulation FD disclosure · Other events
  15. 4 Open-market buy 10% owner bought 165,667 shares at $8.40 ($1,391,686)
  16. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  17. 4 Open-market buy 10% owner bought 248,749 shares at an average $8.46 ($2,103,912)
  18. 4 Open-market buy 10% owner bought 1,459,641 shares at an average $6.73 ($9,826,941)
  19. 3 Insider Initial Statement of Ownership
  20. SCHEDULE 13G/A Stake Statement of Beneficial Ownership

Page 5 of 24 · 471 filings